目的：为有效治疗Ⅲ型前列腺炎患者,临床探究双倍剂量盐酸坦洛新缓释片用于疾病治疗的可行性、优越性。方法选取该院门诊2015年3月一2016年3月期间96例经诊断为Ⅲ型前列腺炎入院治疗患者,按双盲法随机分为两组,包括对照组、大剂量组,各48例。所有患者均给予普乐安片,对照组给予常规剂量盐酸坦洛新缓释片,大剂量组给予双倍剂量药物,观察两组症状改善情况,同时对前列腺液指标情况以及用药期间不良反应情况进行统计。结果大剂量组临床有效率为95.8%,对照组为81.3%,大剂量组较对照组疗效好,P<0.05；用药后大剂量组患者pH值、白细胞计数为(6.3±0.2）、(12.6±4.7）,对照组依次(6.7±0.3）、(15.9±5.2）,两组患者指标均有改善且大剂量组较对照组前列腺液指标恢复程度好,P<0.05。结论临床对于诊断为Ⅲ型前列腺炎患者治疗时,使用双倍剂量的盐酸坦洛新缓释片,不仅能提高临床疾病治疗效果、改善患者症状,同时不良反应少、用药安全性高。%Objective To cure the patients with Type III of prostatitis and explore the feasibility and advantages of double dosage of tamsulosin hydrochloride tablets. Methods Convenient 96 patients with Type III of prostatitis treated from March 2015 to March 2016 in our hospital Outpatient Department were selected. The subjects were randomly divided int two groups, 48 cases each group. All the patients adopted Pule'an tablets. The control group adopted the conventional dosage of tamsulosin hydrochloride tablets; the large dose group adopted the double dosage of tamsulosin hydrochloride tablets. The clinical symptoms, prostatic fluid index and adverse reactions were observed. Results The clinical effective rate of large dose group (95.8%) was larger than control group (81.3%)(P<0.05);The pH value and the white blood cell count were (6.3± 0.2), (12.6±4.7), and the control group (6.7±0.3), (15.9±5.2),the recovery of prostatic fluid index for large dose group was better than control group (P<0.05). Conclusion For patients with Type III of prostatitis, the double dosage of tamsulosin hy-drochloride tablets can enhance the clinical effect, reduce the adverse event rate and improve the clinical safety.
展开▼
